Stay updated on Nivolumab vs Dacarbazine in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page.

Latest updates to the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.5.2 to v3.5.3, indicating a newer build of the page/documentation. This update likely includes minor fixes or enhancements without changing the study details.SummaryDifference0.0%

- Check19 days agoChange DetectedUpdated the study’s listed location/topic entries for Viña del Mar and Valparaiso while removing the prior related topic/location text. No change is shown to the trial’s main eligibility, interventions, or outcome measures.SummaryDifference0.2%

- Check27 days agoChange DetectedRevision: v3.5.2 was added to the page header. Revision: v3.5.0 was removed.SummaryDifference0.0%

- Check34 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the location list. The entry now uses the Italian spelling for the site.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded Naples, Italy, 80131 as a study location and removed Napoli, Italy, 80131.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded Melanoma and related topics (MedlinePlus Genetics) and updated site revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Nivolumab vs Dacarbazine in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page.